Evaluating the impact of mesenchymal stem cell therapy on visual acuity and retinal nerve fiber layer thickness in optic neuropathy patients: a comprehensive systematic review and meta-analysis.
Meta-analysis
Optic neuropathy
Stem cell therapy
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
29 Jul 2024
29 Jul 2024
Historique:
received:
13
04
2024
accepted:
22
07
2024
medline:
30
7
2024
pubmed:
30
7
2024
entrez:
29
7
2024
Statut:
epublish
Résumé
Stem cell therapy has emerged as a potential therapeutic avenue for optic neuropathy patients. To assess its safety and efficacy, we conducted a systematic review and meta-analysis, focusing on the latest evidence pertaining to the improvement of visual acuity (VA) through stem cell therapy. We analyzed Each database from its inception until June 2024. PubMed, Scopus, and Google Scholar were systematically searched to identify the included studies. Data were extracted regarding the year of publication, the name of the first author, sample size, VA (Log Mar), and Retinal Nerve Fiber Layer (RNFL) thickness. PRISMA protocol was used as a guide to perform this meta-analysis. STATA 16 was used for statistical analysis. A total of 66 eyes were examined in seven papers. Based on the meta-analysis, the mean VA (Log MAR) of patients with optic neuropathy improved from 0.90 to 0.65 following stem cell therapy intervention (p-value = 0.001). The thickness of the RNFLs did not demonstrate a significant change (p-value was 0.174). According to this systematic review and meta-analysis, stem cell therapy may improve the visual acuity of patients with optic neuropathy. Aside from the traditional therapy that can be provided to patients with optic neuropathy, stem cell therapy may also be beneficial.
Sections du résumé
BACKGROUND
BACKGROUND
Stem cell therapy has emerged as a potential therapeutic avenue for optic neuropathy patients. To assess its safety and efficacy, we conducted a systematic review and meta-analysis, focusing on the latest evidence pertaining to the improvement of visual acuity (VA) through stem cell therapy.
METHODS
METHODS
We analyzed Each database from its inception until June 2024. PubMed, Scopus, and Google Scholar were systematically searched to identify the included studies. Data were extracted regarding the year of publication, the name of the first author, sample size, VA (Log Mar), and Retinal Nerve Fiber Layer (RNFL) thickness. PRISMA protocol was used as a guide to perform this meta-analysis. STATA 16 was used for statistical analysis.
RESULTS
RESULTS
A total of 66 eyes were examined in seven papers. Based on the meta-analysis, the mean VA (Log MAR) of patients with optic neuropathy improved from 0.90 to 0.65 following stem cell therapy intervention (p-value = 0.001). The thickness of the RNFLs did not demonstrate a significant change (p-value was 0.174).
CONCLUSION
CONCLUSIONS
According to this systematic review and meta-analysis, stem cell therapy may improve the visual acuity of patients with optic neuropathy. Aside from the traditional therapy that can be provided to patients with optic neuropathy, stem cell therapy may also be beneficial.
Identifiants
pubmed: 39075477
doi: 10.1186/s12886-024-03588-2
pii: 10.1186/s12886-024-03588-2
doi:
Types de publication
Journal Article
Systematic Review
Meta-Analysis
Langues
eng
Sous-ensembles de citation
IM
Pagination
316Informations de copyright
© 2024. The Author(s).
Références
da Silva-Junior AJ, Mesentier-Louro LA, Nascimento-dos-Santos G, Teixeira-Pinheiro LC, Vasques JF, Chimeli-Ormonde L, et al. Human mesenchymal stem cell therapy promotes retinal ganglion cell survival and target reconnection after optic nerve crush in adult rats. Stem Cell Res Ther. 2021;12(1):69.
pubmed: 33468246
pmcid: 7814601
doi: 10.1186/s13287-020-02130-7
Almasieh M, Wilson AM, Morquette B, Cueva Vargas JL, Di Polo A. The molecular basis of retinal ganglion cell death in glaucoma. Prog Retin Eye Res. 2012;31(2):152–81.
pubmed: 22155051
doi: 10.1016/j.preteyeres.2011.11.002
Burramsetty AK, Nishimura K, Kishimoto T, Hamzah M, Kuno A, Fukuda A et al. Locus-specific isolation of the nanog chromatin identifies regulators relevant to pluripotency of mouse embryonic stem cells and reprogramming of somatic cells. Int J Mol Sci [Internet]. 2022; 23(23).
Ghaffarieh A, Levin LA. Optic nerve disease and axon pathophysiology. Int Rev Neurobiol. 2012;105:1–17.
pubmed: 23206593
doi: 10.1016/B978-0-12-398309-1.00002-0
Pernet V, Schwab ME. Lost in the jungle: new hurdles for optic nerve axon regeneration. Trends Neurosci. 2014;37(7):381–7.
pubmed: 24874558
doi: 10.1016/j.tins.2014.05.002
Parrilla-Reverter G, Agudo M, Sobrado-Calvo P, Salinas-Navarro M, Villegas-Pérez MP, Vidal-Sanz M. Effects of different neurotrophic factors on the survival of retinal ganglion cells after a complete intraorbital nerve crush injury: a quantitative in vivo study. Exp Eye Res. 2009;89(1):32–41.
pubmed: 19268467
doi: 10.1016/j.exer.2009.02.015
Mesentier-Louro LA, Zaverucha-do-Valle C, Rosado-de-Castro PH, Silva-Junior AJ, Pimentel-Coelho PM, Mendez-Otero R, et al. Bone marrow-derived cells as a Therapeutic Approach to Optic nerve diseases. Stem Cells Int. 2016;2016:5078619.
pubmed: 26649049
doi: 10.1155/2016/5078619
Schwab ME, Kapfhammer JP, Bandtlow CE. Inhibitors Neurite Growth. 1993;16(1):565–95.
Shkarubo AN, Nikolenko VN, Velichko AY, Sinelnikov MY. Cell therapy assisted autotransplantation of olfactory tract into the optic nerve: a potential treatment for optic neuropathy. Med Hypotheses. 2020;143:110104.
pubmed: 32721800
doi: 10.1016/j.mehy.2020.110104
Öner A. Stem cell treatment in Retinal diseases: recent developments. Turkish J Ophthalmol. 2018;48(1):33–8.
doi: 10.4274/tjo.89972
Zhang J, Wu S, Jin ZB, Wang N. Stem Cell-Based Regeneration and Restoration for Retinal Ganglion Cell: Recent Advancements and Current Challenges. Biomolecules. 2021;11(7).
Boia R, Ruzafa N, Aires ID, Pereiro X, Ambrósio AF, Vecino E et al. Neuroprotective Strategies for Retinal Ganglion Cell Degeneration: Current Status and Challenges Ahead. International journal of molecular sciences. 2020;21(7).
Rhee J, Shih KC. Use of Gene Therapy in Retinal Ganglion Cell Neuroprotection: current concepts and future directions. Biomolecules. 2021;11(4).
Patra JK, Das G, Fraceto LF, Campos EVR, Rodriguez-Torres MdP, Acosta-Torres LS, et al. Nano based drug delivery systems: recent developments and future prospects. J Nanobiotechnol. 2018;16(1):71.
doi: 10.1186/s12951-018-0392-8
Agrahari V, Agrahari V, Mandal A, Pal D, Mitra AK. How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches. Expert Opin Drug Deliv. 2017;14(10):1145–62.
pubmed: 27967247
doi: 10.1080/17425247.2017.1272569
Behbehani R. Clinical approach to optic neuropathies. Clin Ophthalmol (Auckland NZ). 2007;1(3):233–46.
Joyce N, Annett G, Wirthlin L, Olson S, Bauer G, Nolta JA. Mesenchymal stem cells for the treatment of neurodegenerative disease. Regen Med. 2010;5(6):933–46.
pubmed: 21082892
doi: 10.2217/rme.10.72
Wang Y, Ji X, Leak RK, Chen F, Cao G. Stem cell therapies in age-related neurodegenerative diseases and stroke. Ageing Res Rev. 2017;34:39–50.
pubmed: 27876573
doi: 10.1016/j.arr.2016.11.002
Ford E, Pearlman J, Ruan T, Manion J, Waller M, Neely GG et al. Human pluripotent stem cells-based therapies for neurodegenerative diseases: current Status and challenges. Cells. 2020;9(11).
Wei M, Yang Z, Li S, Le W. Nanotherapeutic and stem cell therapeutic strategies in neurodegenerative diseases: a Promising Therapeutic Approach. Int J Nanomed. 2023;18:611–26.
doi: 10.2147/IJN.S395010
Kahraman NS, Öner A. Umbilical cord-derived mesenchymal stem cell implantation in patients with optic atrophy. Eur J Ophthalmol. 2021;31(6):3463–70.
pubmed: 33307808
doi: 10.1177/1120672120977824
Dworak DP, Nichols J. A review of optic neuropathies. Dis Mon. 2014;60(6):276–81.
pubmed: 24906673
doi: 10.1016/j.disamonth.2014.03.008
Vidal-Sanz M, Bray GM, Villegas-Pérez MP, Thanos S, Aguayo AJ. Axonal regeneration and synapse formation in the superior colliculus by retinal ganglion cells in the adult rat. J Neuroscience: Official J Soc Neurosci. 1987;7(9):2894–909.
doi: 10.1523/JNEUROSCI.07-09-02894.1987
Rosado-de-Castro PH, Pimentel-Coelho PM, Barbosa da Fonseca LM, de Freitas GR, Mendez-Otero R. The rise of cell therapy trials for stroke: review of published and registered studies. Stem Cells Dev. 2013;22(15):2095–111.
pubmed: 23509917
pmcid: 3715770
doi: 10.1089/scd.2013.0089
Musa M, Zeppieri M, Enaholo ES, Salati C, Parodi PC. Adipose stem cells in Modern-Day Ophthalmology. Clin Pract [Internet]. 2023; 13(1):[230 – 45 pp.].
Chen M, Chen Q, Sun X, Shen W, Liu B, Zhong X, et al. Generation of retinal ganglion–like cells from Reprogrammed mouse fibroblasts. Investig Ophthalmol Vis Sci. 2010;51(11):5970–8.
doi: 10.1167/iovs.09-4504
Mu X, Fu X, Sun H, Beremand PD, Thomas TL, Klein WH. A gene network downstream of transcription factor Math5 regulates retinal progenitor cell competence and ganglion cell fate. Dev Biol. 2005;280(2):467–81.
pubmed: 15882586
doi: 10.1016/j.ydbio.2005.01.028
Mashige KP, Oduntan OA. Retinal nerve fibre layer thickness values and their associations with ocular and systemic parameters in Black South africans. Afr Health Sci. 2016;16(4):1188–94.
pubmed: 28479914
pmcid: 5398468
doi: 10.4314/ahs.v16i4.39
Li L, Yu Y, Lin S, Hu J. Changes in best-corrected visual acuity in patients with dry age-related macular degeneration after stem cell transplantation: systematic review and meta-analysis. Stem Cell Res Ther. 2022;13(1):237.
pubmed: 35672801
pmcid: 9172101
doi: 10.1186/s13287-022-02931-y
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Res ed). 2021;372:n71.
Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4(1):1.
pubmed: 25554246
pmcid: 4320440
doi: 10.1186/2046-4053-4-1
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1):89.
doi: 10.1186/s13643-021-01626-4
Hong QN, Gonzalez-Reyes A, Pluye P. Improving the usefulness of a tool for appraising the quality of qualitative, quantitative and mixed methods studies, the mixed methods Appraisal Tool (MMAT). J Eval Clin Pract. 2018;24(3):459–67.
pubmed: 29464873
doi: 10.1111/jep.12884
Pace R, Pluye P, Bartlett G, Macaulay AC, Salsberg J, Jagosh J, et al. Testing the reliability and efficiency of the pilot mixed methods Appraisal Tool (MMAT) for systematic mixed studies review. Int J Nurs Stud. 2012;49(1):47–53.
pubmed: 21835406
doi: 10.1016/j.ijnurstu.2011.07.002
Weiss JN, Levy S, Benes SC. Stem cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a case report of improvement in relapsing auto-immune optic neuropathy. Neural Regeneration Res. 2015;10(9):1507–15.
doi: 10.4103/1673-5374.165525
Weiss JN, Levy S, Malkin A. Stem cell Ophthalmology Treatment Study (SCOTS) for retinal and optic nerve diseases: a preliminary report. Neural Regeneration Res. 2015;10(6):982–8.
doi: 10.4103/1673-5374.158365
Limoli PG, Limoli C, Vingolo EM, Franzone F, Nebbioso M. Mesenchymal stem and non-stem cell surgery, rescue, and regeneration in glaucomatous optic neuropathy. Stem Cell Res Ther. 2021;12(1):275.
pubmed: 33957957
pmcid: 8101217
doi: 10.1186/s13287-021-02351-4
Weiss JN, Levy S, Benes SC. Stem cell Ophthalmology Treatment Study: bone marrow derived stem cells in the treatment of non-arteritic ischemic optic neuropathy (NAION). Stem cell Invest. 2017;4:94.
doi: 10.21037/sci.2017.11.05
Oner A, Gonen ZB, Sevim DG, Sinim Kahraman N, Unlu M. Six-month results of suprachoroidal adipose tissue-derived mesenchymal stem cell implantation in patients with optic atrophy: a phase 1/2 study. Int Ophthalmol. 2019;39(12):2913–22.
pubmed: 31309439
doi: 10.1007/s10792-019-01141-5
Vilela CAP, Messias A, Calado RT, Siqueira RC, Silva MJL, Covas DT, et al. Retinal function after intravitreal injection of autologous bone marrow-derived mesenchymal stromal cells in advanced glaucoma. Doc Ophthalmol Adv Ophthalmol. 2021;143(1):33–8.
doi: 10.1007/s10633-021-09817-z
Pastor JC, Pastor-Idoate S, López-Paniagua M, Para M, Blazquez F, Murgui E, et al. Intravitreal allogeneic mesenchymal stem cells: a non-randomized phase II clinical trial for acute non-arteritic optic neuropathy. Stem Cell Res Ther. 2023;14(1):261.
pubmed: 37735668
pmcid: 10512539
doi: 10.1186/s13287-023-03500-7
Oner A, Gonen ZB, Sinim N, Cetin M, Ozkul Y. Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther. 2016;7(1):178.
pubmed: 27906070
pmcid: 5134260
doi: 10.1186/s13287-016-0432-y
Jiang C, Moore MJ, Zhang X, Klassen H, Langer R, Young M. Intravitreal injections of GDNF-loaded biodegradable microspheres are neuroprotective in a rat model of glaucoma. Mol Vis. 2007;13:1783–92.
pubmed: 17960131
Schwab ME, Kapfhammer JP, Bandtlow CE. Inhibitors of neurite growth. Annu Rev Neurosci. 1993;16:565–95.
pubmed: 7681638
doi: 10.1146/annurev.ne.16.030193.003025
De Gioia R, Biella F, Citterio G, Rizzo F, Abati E, Nizzardo M et al. Neural Stem Cell Transplantation Neurodegenerative Dis Int J Mol Sci. 2020;21(9).
Sivandzade F, Cucullo L. Regenerative stem cell therapy for neurodegenerative diseases: an overview. Int J Mol Sci. 2021;22(4).
Jagatha B, Divya MS, Sanalkumar R, Indulekha CL, Vidyanand S, Divya TS, et al. In vitro differentiation of retinal ganglion-like cells from embryonic stem cell derived neural progenitors. Biochem Biophys Res Commun. 2009;380(2):230–5.
pubmed: 19167364
doi: 10.1016/j.bbrc.2009.01.038
Chang SK, Kohlgruber AC, Mizoguchi F, Michelet X, Wolf BJ, Wei K, et al. Stromal cell cadherin-11 regulates adipose tissue inflammation and diabetes. J Clin Investig. 2017;127(9):3300–12.
pubmed: 28758901
pmcid: 5669565
doi: 10.1172/JCI86881
Calkins DJ, Pekny M, Cooper ML, Benowitz L. The challenge of regenerative therapies for the optic nerve in glaucoma. Exp Eye Res. 2017;157:28–33.
pubmed: 28153739
pmcid: 5937264
doi: 10.1016/j.exer.2017.01.007
Osborne A, Sanderson J, Martin KR. Neuroprotective effects of Human mesenchymal stem cells and platelet-derived growth factor on human retinal ganglion cells. Stem cells (Dayton. Ohio). 2018;36(1):65–78.
Ding SLS, Kumar S, Mok PL. Cellular reparative mechanisms of mesenchymal stem cells for Retinal diseases. Int J Mol Sci. 2017;18(8).
Hu Y, Grodzki LM, Bartsch S, Bartsch U. Cell-based neuroprotection of retinal ganglion cells in animal models of Optic neuropathies. Biology. 2021;10(11).
Burrello J, Monticone S, Gai C, Gomez Y, Kholia S, Camussi G. Stem cell-derived extracellular vesicles and Immune-Modulation. Front Cell Dev Biol. 2016;4:83.
pubmed: 27597941
pmcid: 4992732
doi: 10.3389/fcell.2016.00083
Wexler SA, Donaldson C, Denning-Kendall P, Rice C, Bradley B, Hows JM. Adult bone marrow is a rich source of human mesenchymal ‘stem’ cells but umbilical cord and mobilized adult blood are not. Br J Haematol. 2003;121(2):368–74.
pubmed: 12694261
doi: 10.1046/j.1365-2141.2003.04284.x
Kern S, Eichler H, Stoeve J, Klüter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells. 2006;24(5):1294–301.
pubmed: 16410387
doi: 10.1634/stemcells.2005-0342
Labrador-Velandia S, Alonso-Alonso ML, Alvarez-Sanchez S, González-Zamora J, Carretero-Barrio I, Pastor JC, et al. Mesenchymal stem cell therapy in retinal and optic nerve diseases: an update of clinical trials. World J stem Cells. 2016;8(11):376–83.
pubmed: 27928464
pmcid: 5120242
doi: 10.4252/wjsc.v8.i11.376
Daiber HF, Gnugnoli DM. Visual acuity. StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2023. StatPearls Publishing LLC.; 2023.
Wang R, Xu B, Xu H. TGF-β1 promoted chondrocyte proliferation by regulating Sp1 through MSC-exosomes derived miR-135b. Cell Cycle (Georgetown Tex). 2018;17(24):2756–65.
pubmed: 30526325
doi: 10.1080/15384101.2018.1556063